Skip to main content

Table 2 Comparison of the different variables on CIS patients with or without conversion to clinically definite MS at the end of follow-up period

From: Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis

 

CIS patients with conversion to clinically definite MS (n = 23)

CIS patients without conversion to clinically definite MS (n = 28)

p

Female sex

17 (73.9%)

21 (75%)

0.93

Mean age at MS diagnosis (years +/- SEM)

31.8 +/- 2.2

31.0 +/- 2.0

0.79

Mean age at treatment initiation (years +/- SEM)

33.4 +/- 2.5

32.1 +/- 2.0

0.69

Mean EDSS at inclusion consultation (+/- SEM)

1.2 +/- 0.2

1.3 +/- 0.2

0.77

Mean ΔEDSS* (+/- SEM)

+0.2 +/- 0.04

0 +/- 0.02

0.70

Mean MFIS score (+/- SEM)

36.0 +/- 4.5

35.8 +/- 3.3

0.98

Number of fatigue patients

13 (56.5%)

16 (57.1%)

0.96

Mean MADRS score (+/- SEM)

3.7 +/- 0.8

3.2 +/- 0.5

0.63

Mean MSTCQ score (+/- SEM)

6.3 +/- 0.8

6.3 +/- 0.9

0.99

Number of NAb + patients

5 (21.7%)

7 (25.0%)

0.78

IFNβ type:

   

- Intramuscular IFNβ-1a

2 (8.7%)

3 (10.7%)

0.43

- Subcutaneous IFNβ-1a

16 (69.6%)

15 (53.6%)

 

- Subcutaneous IFNβ-1b

5 (21.7%)

10 (35.7%)

 
  1. *ΔEDSS = EDSS at the follow-up consultation – EDSS at the inclusion consultation.